|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||14.12 - 14.77|
|52 Week Range||8.69 - 17.20|
|PE Ratio (TTM)||-41.89|
|Earnings Date||Oct 25, 2017 - Oct 30, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||21.86|
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017-- Cytokinetics, Incorporated today announced that the first patient has been dosed in Japan in GALACTIC-HF, the Phase 3 cardiovascular outcomes clinical trial ...
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017-- Cytokinetics, Incorporated today announced that additional results from COSMIC-HF, a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart ...
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.